BioCentury | Jun 26, 2020
Management Tracks

Saunders joins BridgeBio’s board; plus changes at BioXcel, FibroGen, Storm, Athenex, Seres, Chimerix and Catalyst

...enzymes for cancer, hired Josefin-Beate Holz as clinical adviser and CMO. She was CMO of Calypso Biotech B.V....
BioCentury | Feb 27, 2019
Finance

Calypso finds its rhythm

...Strong preclinical data and rising interest in IL-15 modulation enabled six-year-old Calypso Biotech B.V. to raise a €20...
...Assistant Editor Virginia Li and Staff Writer Mark Zipkin contributed to this report. Paul Bonanos, Assistant Editor Calypso Biotech Calypso Biotech...
BioCentury | Feb 22, 2019
Financial News

Merck KGaA spinout Calypso raises first tranche of €20M series A

...intends to focus on eosinophilic esophagitis and an undisclosed orphan disease. Calypso Biotech B.V., Amsterdam, the Netherlands Mark Zipkin Calypso Biotech...
BioCentury | Feb 21, 2019
Financial News

Merck KGaA spinout Calypso raises first tranche of €20M series A

...cancer, Vicari said Calypso intends to focus on eosinophilic esophagitis and an undisclosed orphan disease. Mark Zipkin Calypso Biotech...
BioCentury | Aug 16, 2017
Distillery Therapeutics

Cancer

...testing to treat RA and cystic fibrosis and Phase I testing to treat solid tumors. Calypso Biotech...
BioCentury | Apr 7, 2017
Company News

Calypso, EA Pharma deal

...details. Calypso Biotech S.A. , Geneva, Switzerland EA Pharma Co. Ltd. , Tokyo, Japan Business: Gastrointestinal Julian Zhu CALY-001 Calypso Biotech...
BioCentury | Mar 9, 2017
Finance

Pharmas learn their A, B, seeds

...and RNA therapeutics company RaNA Therapeutics Inc. , and notable leveragable single asset investments include Calypso Biotech...
...Inc. (NASDAQ:BIIB), Cambridge, Mass. Boehringer Ingelheim GmbH, Ingelheim, Germany Bristol-Myers Squibb Co.(NYSE:BMY), New York, N.Y. Calypso Biotech...
BioCentury | Aug 11, 2016
Distillery Therapeutics

Therapeutics: Matrix metalloproteinase 9 (MMP9); netrin 1 (NTN1)

...Phase I testing to treat chronic obstructive pulmonary disease (COPD), rheumatoid arthritis and solid tumors. Calypso Biotech...
BioCentury | Jul 11, 2013
Cover Story

Debugging Crohn's disease

...vivo effects of the compounds independently of Ceacam6 overexpression. Vicari and Chvatchko are founders of Calypso Biotech...
...doi:10.1038/scibx.2013.644 Published online July 11, 2013 Companies and Institutions Mentioned AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Calypso Biotech...
BioCentury | May 27, 2013
Emerging Company Profile

Calypso: Fistula fix

...the end of 2015 or early in 2016 for both diseases. Companies and Institutions Mentioned Calypso Biotech...
...S.A. , Geneva, Switzerland iDD Biotech , Dardilly, France Merck KGaA (Xetra:MRK), Darmstadt, Germany Sidebars Calypso Biotech...
Items per page:
1 - 10 of 14
BioCentury | Jun 26, 2020
Management Tracks

Saunders joins BridgeBio’s board; plus changes at BioXcel, FibroGen, Storm, Athenex, Seres, Chimerix and Catalyst

...enzymes for cancer, hired Josefin-Beate Holz as clinical adviser and CMO. She was CMO of Calypso Biotech B.V....
BioCentury | Feb 27, 2019
Finance

Calypso finds its rhythm

...Strong preclinical data and rising interest in IL-15 modulation enabled six-year-old Calypso Biotech B.V. to raise a €20...
...Assistant Editor Virginia Li and Staff Writer Mark Zipkin contributed to this report. Paul Bonanos, Assistant Editor Calypso Biotech Calypso Biotech...
BioCentury | Feb 22, 2019
Financial News

Merck KGaA spinout Calypso raises first tranche of €20M series A

...intends to focus on eosinophilic esophagitis and an undisclosed orphan disease. Calypso Biotech B.V., Amsterdam, the Netherlands Mark Zipkin Calypso Biotech...
BioCentury | Feb 21, 2019
Financial News

Merck KGaA spinout Calypso raises first tranche of €20M series A

...cancer, Vicari said Calypso intends to focus on eosinophilic esophagitis and an undisclosed orphan disease. Mark Zipkin Calypso Biotech...
BioCentury | Aug 16, 2017
Distillery Therapeutics

Cancer

...testing to treat RA and cystic fibrosis and Phase I testing to treat solid tumors. Calypso Biotech...
BioCentury | Apr 7, 2017
Company News

Calypso, EA Pharma deal

...details. Calypso Biotech S.A. , Geneva, Switzerland EA Pharma Co. Ltd. , Tokyo, Japan Business: Gastrointestinal Julian Zhu CALY-001 Calypso Biotech...
BioCentury | Mar 9, 2017
Finance

Pharmas learn their A, B, seeds

...and RNA therapeutics company RaNA Therapeutics Inc. , and notable leveragable single asset investments include Calypso Biotech...
...Inc. (NASDAQ:BIIB), Cambridge, Mass. Boehringer Ingelheim GmbH, Ingelheim, Germany Bristol-Myers Squibb Co.(NYSE:BMY), New York, N.Y. Calypso Biotech...
BioCentury | Aug 11, 2016
Distillery Therapeutics

Therapeutics: Matrix metalloproteinase 9 (MMP9); netrin 1 (NTN1)

...Phase I testing to treat chronic obstructive pulmonary disease (COPD), rheumatoid arthritis and solid tumors. Calypso Biotech...
BioCentury | Jul 11, 2013
Cover Story

Debugging Crohn's disease

...vivo effects of the compounds independently of Ceacam6 overexpression. Vicari and Chvatchko are founders of Calypso Biotech...
...doi:10.1038/scibx.2013.644 Published online July 11, 2013 Companies and Institutions Mentioned AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Calypso Biotech...
BioCentury | May 27, 2013
Emerging Company Profile

Calypso: Fistula fix

...the end of 2015 or early in 2016 for both diseases. Companies and Institutions Mentioned Calypso Biotech...
...S.A. , Geneva, Switzerland iDD Biotech , Dardilly, France Merck KGaA (Xetra:MRK), Darmstadt, Germany Sidebars Calypso Biotech...
Items per page:
1 - 10 of 14